Henlius and Amberstone Partner to Develop Next-Generation Conditionally Activated TCEs for Solid Tumours
Shanghai Henlius Biotech, Inc. (2696.HK) today announced that it has entered into a global collaboration and license agreement with Amberstone Biosciences (“Amberstone”), a U.S.-based biotechnology company dedicated to developing next-generation tumour-activated antibody therapeutics. The collaboration will leverage Amberstone’s proprietary T-MATE™ (Tumour Microenvironment Activated ThErapeutics) platform to develop conditionally activated T-cell engagers (TCEs) based on up to two targets designated by Henlius for the treatment of solid tumours.
Share:
More News
Jian Peng, PhD, CEO of Earendil Labs, said: “Genentech is a pioneer in defining modern biologics cancer medicine. Earendil Labs is building an AI-driven high-throughput biology platform that effectively integrates AI directly into biologics research and development—from predictive protein modeling and generative protein design to rapid experimental validation. By combining
“The IDMC’s recommendation to continue our Phase 2 MRD study without modification provides important independent validation of the favorable safety profile we have consistently observed across our clinical development program,” said Stacy Lindborg, Ph.D., President and Chief Executive Officer of IMUNON. “Across our completed and ongoing clinical studies, we have
“These Phase 3 results reinforce the potential of ZENBEXUS to advance treatment for patients with relapsed or refractory multiple myeloma,” said Cristian Massacesi, executive vice president, chief medical officer and head of development, Bristol Myers Squibb. “As the first therapy in multiple myeloma to demonstrate superiority on an MRD-negative complete
“Initiating IND-enabling studies is a defining milestone for Beactica and for the BEA‑17 programme,” said Dr Per Källblad, Chief Executive Officer of Beactica Therapeutics. “With a first-in-class mechanism and compelling preclinical efficacy in combination with standard of care, we are now executing the rigorous safety and manufacturing programme that will